Lung cancer varies widely from patient to patient, and that diversity makes it hard to find effective treatments. Researchers at the Berlin Institute of Health at Charité (BIH) have developed a method to evaluate multiple therapeutic approaches on patient-derived “tumoroids” – miniature tumors grown from tissue removed during surgery at Charité. By testing drug responses across these tumoroids, the team showed that therapeutic success depends on a complex interplay of tumor characteristics rather than a single factor. Their results suggest that tumoroid-based testing could help physicians tailor treatments to individual patients and improve clinical decision-making.